Pfizer Inc. (NYSE:PFE) Shares Sold by Cambridge Trust Co.

Cambridge Trust Co. cut its position in shares of Pfizer Inc. (NYSE:PFE) by 7.9% during the 1st quarter, according to the company in its most recent filing with the SEC. The firm owned 67,564 shares of the biopharmaceutical company’s stock after selling 5,824 shares during the quarter. Cambridge Trust Co.’s holdings in Pfizer were worth $1,875,000 as of its most recent filing with the SEC.

Other hedge funds also recently modified their holdings of the company. Argus Investors Counsel Inc. boosted its position in Pfizer by 17.2% during the fourth quarter. Argus Investors Counsel Inc. now owns 43,315 shares of the biopharmaceutical company’s stock valued at $1,247,000 after purchasing an additional 6,350 shares during the last quarter. Addenda Capital Inc. boosted its position in Pfizer by 29.7% during the fourth quarter. Addenda Capital Inc. now owns 198,325 shares of the biopharmaceutical company’s stock valued at $5,710,000 after purchasing an additional 45,380 shares during the last quarter. Integrated Investment Consultants LLC boosted its position in Pfizer by 21.8% during the fourth quarter. Integrated Investment Consultants LLC now owns 26,730 shares of the biopharmaceutical company’s stock valued at $770,000 after purchasing an additional 4,779 shares during the last quarter. DORCHESTER WEALTH MANAGEMENT Co lifted its position in shares of Pfizer by 3.1% in the fourth quarter. DORCHESTER WEALTH MANAGEMENT Co now owns 241,092 shares of the biopharmaceutical company’s stock worth $6,941,000 after buying an additional 7,305 shares during the last quarter. Finally, Heartland Bank & Trust Co lifted its position in shares of Pfizer by 64.0% in the fourth quarter. Heartland Bank & Trust Co now owns 13,860 shares of the biopharmaceutical company’s stock worth $399,000 after buying an additional 5,409 shares during the last quarter. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Pfizer Trading Down 0.7 %

Pfizer stock traded down $0.22 during trading hours on Friday, reaching $30.43. The stock had a trading volume of 42,364,712 shares, compared to its average volume of 37,871,120. The stock has a market cap of $172.43 billion, a PE ratio of -507.08, a PEG ratio of 1.07 and a beta of 0.69. Pfizer Inc. has a 52 week low of $25.20 and a 52 week high of $37.19. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.05 and a quick ratio of 0.78. The company has a fifty day simple moving average of $28.73 and a 200-day simple moving average of $27.84.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, July 30th. The biopharmaceutical company reported $0.60 earnings per share for the quarter, beating analysts’ consensus estimates of $0.46 by $0.14. The firm had revenue of $13.28 billion for the quarter, compared to analyst estimates of $12.96 billion. Pfizer had a negative net margin of 4.66% and a positive return on equity of 8.31%. The company’s revenue for the quarter was up 2.1% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.67 EPS. Analysts forecast that Pfizer Inc. will post 2.68 EPS for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 3rd. Investors of record on Friday, July 26th will be paid a dividend of $0.42 per share. This represents a $1.68 annualized dividend and a yield of 5.52%. The ex-dividend date is Friday, July 26th. Pfizer’s payout ratio is currently -2,799.53%.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on PFE. StockNews.com raised Pfizer from a “hold” rating to a “buy” rating in a research report on Thursday. Cantor Fitzgerald reissued an “overweight” rating and issued a $45.00 target price on shares of Pfizer in a report on Wednesday. Wells Fargo & Company upped their price objective on Pfizer from $28.00 to $30.00 and gave the stock an “equal weight” rating in a report on Wednesday. BMO Capital Markets reiterated an “outperform” rating and set a $36.00 target price (up previously from $33.00) on shares of Pfizer in a research report on Thursday, May 2nd. Finally, Barclays upped their target price on shares of Pfizer from $30.00 to $32.00 and gave the company an “equal weight” rating in a research report on Wednesday. Eight investment analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to MarketBeat, Pfizer currently has an average rating of “Hold” and a consensus target price of $34.58.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.